Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus S-1 versus S-1 alone as adjuvant therapy after curative resection for stage III gastric cancer
jRCTs041180146Phase 3Completed
- Sponsor
- Japan Clinical Cancer Research Organization
- Start
- Apr 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric cancer (GC) comparing S-1 plus docetaxel with S-1 alone (2 arms). Primary endpoint: 3-year relapse-free survival. Started Apr 2013; status: completed.
02
Drugs
docetaxeltegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs041180146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180146.